A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

被引：0
|
作者：
Rischin, D. [1 ,2 ]
Fury, M. G. [3 ]
Lowy, I. [3 ]
Stankevich, E. [3 ]
Li, S. [3 ]
Han, H. [3 ]
Porceddu, S. V. [4 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Regeneron Pharmaceut Inc, Clin Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Univ Queensland, Sch Med, Princess Alexandra Hosp, Dept Radiat Oncol, Herston, Qld, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1372TiP
引用
收藏
页码：560 / 560
页数：1
相关论文
共 50 条
  • [1] A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
    Rischin, Danny
    Fury, Matthew G.
    Lowy, Israel
    Stankevich, Elizabeth
    Han, Hyunsil
    Porceddu, Sandro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
    Rischin, Danny
    Brungs, Daniel
    Day, Fiona
    Christie, Hayden Robert
    Patel, Vishal A.
    Adams, Gerard
    Jackson, James Estes
    Schurmann, Maite De Liz Vassen
    Kirtbaya, Dmitry
    Shin, Thuzar M.
    Hart, Christopher David
    Stankevich, Elizabeth
    Li, Siyu
    Lowy, Israel
    Han, Hyunsil
    Fury, Matthew G.
    Porceddu, Sandro
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
    Rischin, D.
    Brungs, D.
    Day, F.
    Christie, H.
    Patel, V. A.
    Adams, G.
    Jackson, J. E.
    Schurmann, M. D. L. V.
    Kirtbaya, D.
    Shin, T. M.
    Hart, C. D.
    Stankevich, E.
    Li, S.
    Lowy, I.
    Han, H.
    Fury, M. G.
    Porceddu, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E610 - E611
  • [4] A Phase 3 randomized Double-blind Study of adjuvant Cemiplimab versus Placebo after Surgery and Radiotherapy for Patients with cutaneous squamous Cell Carcinoma Patients with high Risks
    Rischin, D.
    Fury, M. G.
    Lowy, I.
    Stankevich, E.
    Li, S.
    Han, H.
    Porceddu, S. V.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 74 - 74
  • [5] KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma
    Geiger, Jessica
    Daniels, Gregory
    Cohen, Ezra
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona
    Chang, Anne Lynn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
    Eggermont, Alexander M. M.
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo A.
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Konto, Cyril
    Hoos, Axel
    de Pril, Veerle
    Gurunath, Ravichandra Karra
    de Schaetzen, Gaetan
    Suciu, Stefan
    Testori, Alessandro
    LANCET ONCOLOGY, 2015, 16 (05) : 522 - 530
  • [7] Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study
    Schenker, Michael
    Klochikhin, Mikhail
    Bratland, Ase
    Kirtbaya, Dmitry
    Guminski, Alexander
    Dzienis, Marcin
    Schmults, Chrysalyne
    Ge, Joy Y.
    Yuan, Jianda
    Lee, Jenny
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB135 - AB135
  • [8] Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma.
    Lowe, Michael C.
    Yushak, Melinda Lynne
    Delman, Keith A.
    Rizzo, Monica
    Claar, Caroline
    Schmidt, Allyson
    Switchenko, Jeffrey M.
    Lawson, David H.
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
    Harrington, Kevin
    Temam, Stephane
    Mehanna, Hisham
    D'Cruz, Anil
    Jain, Minish
    D'Onofrio, Ida
    Manikhas, Georgy
    Horvath, Zsuzsanna
    Sun, Yan
    Dietzsch, Stefan
    Dubinsky, Pavol
    Holeckova, Petra
    El-Hariry, Iman
    Franklin, Natalie
    Biswas-Baldwin, Nigel
    Legenne, Philippe
    Wissel, Paul
    Netherway, Thelma
    Farrell, John
    Ellis, Catherine
    Wang-Silvanto, Jing
    Amonkar, Mayur
    Ahmed, Nazma
    Santillana, Sergio
    Bourhis, Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4202 - +
  • [10] A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
    Bajorin, D.
    Galsky, M. D.
    Gschwend, J. E.
    Tomita, Y.
    Azrilevich, A.
    Witjes, F.
    ANNALS OF ONCOLOGY, 2017, 28
12345